IKIlankumaran Kaliamoorthy

Ilankumaran Kaliamoorthy

*This is an algorithmically generated author record based on publicly available information.

Ilankumaran Kaliamoorthy has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Mohamed Rela

    The Institute of Liver Disease & Transplantation, Dr.Rela Institute & Medical Centre, Bharath Institute of Higher Education & Research, Chennai, India

    9 shared publications
  • Ashwin Rammohan

    The Institute of Liver Disease & Transplantation, Dr.Rela Institute & Medical Centre, Bharath Institute of Higher Education & Research, Chennai, India

    8 shared publications
  • Mettu Srinivas Reddy

    Department of Liver Transplant and Hepatopancreaticobiliary Surgery, Gleneagles Global Health City, Perumbakkam, Chennai, India

    6 shared publications
  • Mukul Vij

    Institute of Liver Disease & Transplantation, Dr Rela Institute & Medical centre, Bharath Institute of Higher Education and Research, Chennai, India

    5 shared publications
  • Rajesh Rajalingam

    Department of HPB Surgery and Liver Transplantation, Institute of Liver Diseases and Transplantation, Dr. Rela Institute and Medical Centre, Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India

    4 shared publications
  • Abdul Rahman Hakeem

    Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London SE5 9RS, United Kingdom.

    3 shared publications

Latest Publications

  • Granuloma rich hepatocellular carcinoma (GrHCC): Clinicopathologic and genomic characterization

    by Mukul Vij, Lexmi Priya Raju, Dinesh Jothimani, Evangeline Simon, Subathra Radhakrishnan, Catherine Ann Martin, Gowripriya Gowrishankar, Komalavalli Subbiah, Rajesh Rajalingam, Ilankumaran Kaliamoorthy, et al.


  • Open Access

    Update on the Pathology of Pediatric Liver Tumors: A Pictorial Review

    by Priyanka Bhagat, Mukul Vij, Lexmi Priya Raju, Gowripriya Gowrishankar, Jagadeesh Menon, Naresh Shanmugam, Ilankumaran Kaliamoorthy, Ashwin Rammohan, Mohamed Rela

    Liver tumors in children are uncommon and show remarkable morphologic heterogeneity. Pediatric tumors may arise from either the epithelial or mesenchymal component of the liver and rarely may also show both lines of differentiation. Both benign and malignant liver tumors have been reported in children. The most common pediatric liver tumors by age are benign hepatic infantile hemangiomas in neonates and infants, malignant hepatoblastoma in infants and toddlers, and malignant hepatocellular carcinoma in teenagers. Here, we provide an up-to-date review of pediatric liver tumors. We discuss the clinical presentation, imaging findings, pathology, and relevant molecular features that can help in the correct identification of these tumors, which is important in managing these children.


  • Propensity score matched analysis and risk stratification of donors with G6PD deficiency in living donor liver transplantation

    by P. Krishna, A. Rammohan, R. Rajalingam, G. Narasimhan, R. Cherukuru, D. Sachan, A. Rajakumar, I. Kaliamoorthy, M. S. Reddy, M. Rela

    Introduction Glucose 6 phosphate dehydrogenase (G6PD) deficiency (G6PDd) can trigger hemolysis following surgical stress. Differentiating G6PDd-related post-operative hemolytic episodes (PHE) and post-hepatectomy liver failure may be challenging especially in living donors where donor safety is paramount. We analysed outcomes of our cohort of G6PDd liver donors. Methods G6PDd individuals with no evidence of hemolysis were considered as living donors if there was no alternative family donor. Outcomes of G6PDd donors undergoing left lateral/left lobe donation (Group LL) and right lobe donation (Group RL) were compared with non-G6PDd donors matched in a 1:3 ratio using propensity score matching. Results 59 G6PDd donors (5.8% of 1011) underwent living donor hepatectomy (LiDH) during the study period. LL-G6PDd donors (22.37%) had higher post-operative peak bilirubin level compared to matched controls, but no difference in morbidity or need for post-operative blood transfusion.RL-G6PDd donors (37.63%) had higher peak bilirubin level, morbidity (16.2% vs. 3.6%, p = 0.017) and more post-operative blood transfusion (21.6% vs. 6.4%, p = 0.023) as compared to matched non-G6PDd cohort. Four RL-G6PDd donors (10.8%) developed PHE. Low G6PD activity (15% vs. 40%, p = 0.034) and lower future liver remnant (FLR) (34.3% vs. 37.8%, p = 0.05) were identified as risk factors for PHE. Conclusion We report the largest to-date series of G6PDd individuals undergoing LiDH and confirm the safety of LL donation in G6PDd. Our analysis identifies specific risk factors for PHE and suggests that right lobe LiDH be avoided in individuals with less than 25% G6PD activity when the FLR is less than 36%.


  • Frequent expression of PD-L1 in lymphocyte-rich hepatocellular carcinoma: A report of 4 cases

    by Mukul Vij, Fadl H. Veerankutty, Lexmi Priya Raju, Gowripriya Gowrishankar, Rajesh Rajalingam, Dinesh Jothimani, Ilankumaran Kaliamoorthy, Ashwin Rammohan, Mohamed Rela


  • Pathologic and Immunophenotypic Characterization of Syncytial Giant Cell Variant of Pediatric Hepatocellular Carcinoma. A Distinct Subtype

    by Mukul Vij, Jagadeesh Menon, Komalavalli Subbiah, Lexmi Priya Raju, Gowripriya Gowrisankar, Naresh Shanmugum, Ilankumaran Kaliamoorthy, Ashwin Rammohan, Mohamed Rela

    Hepatocellular carcinoma (HCC) in pediatrics has a uniformly poor prognosis. Complete surgical resection or liver transplantation remain the only curative options. In contrast to adult HCC, literat...


  • Open Access

    Anatomical variations of left hepatic vein and outflow reconstruction techniques in pediatric living donor liver transplantation

    by Sadhana Shankar, Ashwin Rammohan, Vasanthakumar Gunasekaran, Gomathy Narasimhan, Rajesh Rajalingam, Kumar Palaniappan, Rathnavel Kanagavelu, Akila Rajkumar, Ilankumaran Kaliamoorthy, Mohamed Rela


  • Living Donor Liver Transplantation for Budd‐Chiari Syndrome: A Propensity Score‐Matched Analysis

    by V. Gunasekaran, M. S. Reddy, A. Rammohan, N. Shanmugam, D. Thiruchunapalli, R. G. Kanagavelu, I. Kaliamoorthy, M. Rela

    Introduction: There are unique technical and management challenges associated with living donor liver transplantation (LDLT) for Budd‐Chiari Syndrome (BCS). The outcomes of LDLT for BCS in comparison to other indications remain unclear and warrant elucidation.Methods: Data of 24 BCS patients who underwent LDLT between January 2012 and June 2019 were analyzed. There were 20 adults and 4 children. The early and long‐term outcomes of adult LDLT BCS patients were compared to a control group of LDLT patients for other indications and matched using propensity scoring methodology.Results: Primary BCS was observed in 18 (90%) patients. Caval replacement was performed in 7 (35%) patients. Early and late hepatic venous outflow tract (HVOT) complications were seen in 1 (5%) and 3 (15%) patients. Preoperative acute kidney injury was identified as a risk factor for mortality in the BCS cohort (p = 0.013). On comparison, BCS recipients were younger with fewer comorbidities, more large volume ascites and higher rates of PVT. They also had longer cold ischemia time, increased blood loss and transfusion requirements, increased hospital stay, and higher late outflow complications. The 1‐year and 3‐year survivals were similar to non‐BCS cohort (84.2% vs. 94% and 71.3% vs. 91.9%, respectively, log rank test p = 0.09).Conclusion: LDLT is a good option for symptomatic BCS who have failed non‐transplant interventions. The clinical and risk factor profile of BCS recipients is distinct from non‐BCS recipients. By following an algorithmic management protocol, we show on propensity‐score matched analysis that outcomes of LDLT for BCS are similar to non‐BCS indications.


  • Open Access

    Living Donor Liver Transplantation for Budd-Chiari Syndrome: A Propensity Score-Matched Analysis

    by Vasanthakumar Gunasekaran, Mettu Srinivas Reddy, Ashwin Rammohan, Naresh P Shanmugam, Deepashree Thirchunapalli, Rathnavel G Kanagavelu, Ilankumaran Kaliamoorthy, Mohamed Rela

    Introduction: There are unique technical and management challenges associated with living donor liver transplantation (LDLT) for Budd-Chiari Syndrome (BCS). The outcomes of LDLT for BCS in comparison to other indications remains unclear and warrants elucidation. Methods: Data of 24 BCS patients who underwent LDLT between January 2012 and June 2019 were analyzed. There were 20 adults and 4 children. The early and long-term outcomes of adult LDLT BCS patients were compared to a control group of LDLT patients for other indications and matched using propensity scoring methodology. Results: Primary BCS was observed in 22(91.7%) patients. Caval replacement was performed in 7(29.1%) patients. Early and late hepatic venous outflow tract (HVOT) complications were seen in 1(5.5%) and 3(16.7%) patients. Preoperative acute kidney injury was identified as a risk factor for mortality in the BCS cohort (p =0.013). On comparison, BCS recipients were younger with fewer comorbidities, more large volume ascites and higher rates of PVT. They also had longer cold ischemia time, increased blood loss and transfusion requirements, increased hospital stay, and higher late outflow complications. The 1-year and 3-year survivals were similar to non-BCS cohort (84.2% vs 94% and 70% vs 91.9%, respectively, log rank test p=0.09). Conclusion: LDLT is remains a good option for symptomatic BCS who have failed non-transplant interventions. The clinical and risk factor profile of BCS recipients is distinct from non-BCS recipients. By following an algorithmic management protocol, we show on propensity-score matched analysis that outcomes of LDLT for BCS are similar to non-BCS indications.

  • Propensity Score–Matched Analysis of Posttransplant Outcomes in Living Donor Liver Transplantation for Older Adult Recipients

    by Abdul Rahman Hakeem, Rukhaiya Fathima, Hrishikesh Padmanaban, Kulaseharan Haribabu, Rajesh Rajalingam, Kumar Palaniappan, Dinesh Jothimani, Rathan Kanagavelu, Akila Rajakumar, Ilankumaran Kaliamoorthy, et al.

    The impact of increasing recipient age on morbidity and mortality following living donor liver transplantation (LDLT) remains controversial. The study aims to analyze the impact of recipient age on outcomes following LDLT. Data on adult LDLTs performed between November 2009 and February 2020 were retrieved from a prospectively maintained database. Patients were stratified into 2 groups based on recipient age: 18 to 65 years (younger adults) and >65 years (older adults). Propensity score matching (PSM) using nearest‐neighbor matching was used to match each older recipient with up to 2 younger adult recipients using multiple preoperative parameters. Outcomes evaluated were duration of ventilation, need for reintubation, tracheostomy, intensive care unit (ICU) readmission, length of ICU and hospital stays, postoperative complications, reoperation within 90 days, and patient survival. A total of 801 adult LDLT recipients were included in the study; 751 (93.7%) were younger adults, and 50 (6.3%) were older adults. Older recipients were more likely to be diabetic (60.0% versus 39.7%) and hypertensive (44.0% versus 20.4%) with preexisting cardiac disease (28.0% versus 11.2%). However, their pretransplant Model for End‐Stage Liver Disease score was significantly lower (14.5 versus 17.7), and they were more likely to receive a transplant because of hepatocellular carcinoma (38.0% versus 17.7%). Older recipients had longer durations of ventilation after LT both before (3.7 versus 1.9 days) and after PSM (4.0 versus 1.5 days). After PSM, the 30‐day (13.0% versus 2.4%), 90‐day (15.2% and 2.4%), and overall mortality rates (21.7% versus 7.1%) were significantly higher for older recipients when compared with younger recipients. There was no difference between the younger and older recipients with respect to other postoperative outcomes. This propensity score–matched study shows that the older LDLT recipients have higher 30‐day, 90‐day, 1‐year, and 5‐year mortality rates when compared with matched younger counterparts.